Does RIBOCICLIB Cause Malignant neoplasm progression? 2,468 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 2,468 reports of Malignant neoplasm progression have been filed in association with RIBOCICLIB (KISQALI). This represents 8.8% of all adverse event reports for RIBOCICLIB.
2,468
Reports of Malignant neoplasm progression with RIBOCICLIB
8.8%
of all RIBOCICLIB reports
683
Deaths
585
Hospitalizations
How Dangerous Is Malignant neoplasm progression From RIBOCICLIB?
Of the 2,468 reports, 683 (27.7%) resulted in death, 585 (23.7%) required hospitalization, and 116 (4.7%) were considered life-threatening.
Is Malignant neoplasm progression Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for RIBOCICLIB. However, 2,468 reports have been filed with the FAERS database.
What Other Side Effects Does RIBOCICLIB Cause?
Neutropenia (3,585)
Nausea (3,404)
Fatigue (3,327)
Death (2,452)
Vomiting (1,953)
Diarrhoea (1,830)
White blood cell count decreased (1,683)
Pain (1,637)
Metastases to bone (1,538)
Dyspnoea (1,473)
What Other Drugs Cause Malignant neoplasm progression?
PEMBROLIZUMAB (10,111)
NIVOLUMAB (9,363)
ENZALUTAMIDE (4,696)
CARBOPLATIN (4,177)
EVEROLIMUS (3,789)
PACLITAXEL (3,484)
LETROZOLE (3,445)
IPILIMUMAB (3,296)
FULVESTRANT (3,221)
LENVATINIB (2,929)
Which RIBOCICLIB Alternatives Have Lower Malignant neoplasm progression Risk?
RIBOCICLIB vs RIBOFLAVIN
RIBOCICLIB vs RIBOFLAVIN 5'-PHOSPHATE
RIBOCICLIB vs RIBOFLAVIN 5^-PHOSPHATE
RIBOCICLIB vs RIFABUTIN
RIBOCICLIB vs RIFAMPICIN